Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma

Glaucoma is the leading cause of irreversible vision loss worldwide, and reduction of intraocular pressure (IOP) is the only factor that can be interfered to delay disease progression. As the first line and preferred method to treat glaucoma, eye drops have many shortcomings, such as low bioavailabi...

Full description

Bibliographic Details

Published in:	Drug Delivery
Main Authors:	Yujin Zhao, Chang Huang, Zhutian Zhang, Jiaxu Hong, Jianjiang Xu, Xinghuai Sun, Jianguo Sun
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-12-01
Subjects:	sustained release brimonidine intraocular pressure (iop) glaucoma conjunctival sac implant
Online Access:	http://dx.doi.org/10.1080/10717544.2022.2039806